240 related articles for article (PubMed ID: 23404471)
1. Degradation of p53 by natural variants of the E6 protein of human papillomavirus type 16.
Yi JW; Jang M; Kim SJ; Kim SS; Rhee JE
Oncol Rep; 2013 Apr; 29(4):1617-22. PubMed ID: 23404471
[TBL] [Abstract][Full Text] [Related]
2. p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene.
Spitkovsky D; Aengeneyndt F; Braspenning J; von Knebel Doeberitz M
Oncogene; 1996 Sep; 13(5):1027-35. PubMed ID: 8806692
[TBL] [Abstract][Full Text] [Related]
3. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
[TBL] [Abstract][Full Text] [Related]
4. Activities of human papillomavirus 16 E6 natural variants in human keratinocytes.
Asadurian Y; Kurilin H; Lichtig H; Jackman A; Gonen P; Tommasino M; Zehbe I; Sherman L
J Med Virol; 2007 Nov; 79(11):1751-60. PubMed ID: 17854024
[TBL] [Abstract][Full Text] [Related]
5. RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53.
Sima N; Wang W; Kong D; Deng D; Xu Q; Zhou J; Xu G; Meng L; Lu Y; Wang S; Ma D
Apoptosis; 2008 Feb; 13(2):273-81. PubMed ID: 18060502
[TBL] [Abstract][Full Text] [Related]
6. The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer.
Pillai MR; Halabi S; McKalip A; Jayaprakash PG; Rajalekshmi TN; Nair MK; Herman B
Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):329-35. PubMed ID: 9162297
[TBL] [Abstract][Full Text] [Related]
7. Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells.
Munagala R; Kausar H; Munjal C; Gupta RC
Carcinogenesis; 2011 Nov; 32(11):1697-705. PubMed ID: 21859835
[TBL] [Abstract][Full Text] [Related]
8. HPV16 E6 natural variants exhibit different activities in functional assays relevant to the carcinogenic potential of E6.
Lichtig H; Algrisi M; Botzer LE; Abadi T; Verbitzky Y; Jackman A; Tommasino M; Zehbe I; Sherman L
Virology; 2006 Jun; 350(1):216-27. PubMed ID: 16519914
[TBL] [Abstract][Full Text] [Related]
9. [Human papillomavirus type 16 E6 oncogene and expression of P53, RB and PCNA in human cervical carcinoma].
Bian J; Yu X; Dong J; Zhao W; Zhou Y; Luan Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):271-3. PubMed ID: 15617346
[TBL] [Abstract][Full Text] [Related]
10. High-risk HPV E6 oncoproteins assemble into large oligomers that allow localization of endogenous species in prototypic HPV-transformed cell lines.
García-Alai MM; Dantur KI; Smal C; Pietrasanta L; de Prat-Gay G
Biochemistry; 2007 Jan; 46(2):341-9. PubMed ID: 17209544
[TBL] [Abstract][Full Text] [Related]
11. Reduced p21(WAF1/CIP1) via alteration of p53-DDX3 pathway is associated with poor relapse-free survival in early-stage human papillomavirus-associated lung cancer.
Wu DW; Liu WS; Wang J; Chen CY; Cheng YW; Lee H
Clin Cancer Res; 2011 Apr; 17(7):1895-905. PubMed ID: 21325288
[TBL] [Abstract][Full Text] [Related]
12. PDZ Domain-Containing Protein NHERF-2 Is a Novel Target of Human Papillomavirus 16 (HPV-16) and HPV-18.
Saidu NEB; Filić V; Thomas M; Sarabia-Vega V; Đukić A; Miljković F; Banks L; Tomaić V
J Virol; 2019 Dec; 94(1):. PubMed ID: 31597772
[TBL] [Abstract][Full Text] [Related]
13. Functional consequences of directed mutations in human papillomavirus E6 proteins: abrogation of p53-mediated cell cycle arrest correlates with p53 binding and degradation in vitro.
Slebos RJ; Kessis TD; Chen AW; Han SM; Hedrick L; Cho KR
Virology; 1995 Apr; 208(1):111-20. PubMed ID: 11831691
[TBL] [Abstract][Full Text] [Related]
14. The immortalizing and transforming ability of two common human papillomavirus 16 E6 variants with different prevalences in cervical cancer.
Richard C; Lanner C; Naryzhny SN; Sherman L; Lee H; Lambert PF; Zehbe I
Oncogene; 2010 Jun; 29(23):3435-45. PubMed ID: 20383192
[TBL] [Abstract][Full Text] [Related]
15. Papillomavirus type 16 E6/E7 and human telomerase reverse transcriptase in esophageal cell immortalization and early transformation.
Zhang H; Jin Y; Chen X; Jin C; Law S; Tsao SW; Kwong YL
Cancer Lett; 2007 Jan; 245(1-2):184-94. PubMed ID: 16488074
[TBL] [Abstract][Full Text] [Related]
16. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro.
Hampson L; Kitchener HC; Hampson IN
Antivir Ther; 2006; 11(6):813-25. PubMed ID: 17310826
[TBL] [Abstract][Full Text] [Related]
17. Degradation of p53 by HPV16-E6 variants isolated from cervical cancer specimens of Moroccan women.
Hadami K; Saby C; Dakka N; Collin G; Attaleb M; Khyatti M; Filali-Maltouf A; Morjani H; El Mzibri M
Gene; 2021 Jul; 791():145709. PubMed ID: 33984442
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines.
Mantovani F; Banks L
Oncogene; 1999 Jun; 18(22):3309-15. PubMed ID: 10362351
[TBL] [Abstract][Full Text] [Related]
19. Neocarzinostatin induces an effective p53-dependent response in human papillomavirus-positive cervical cancer cells.
Bañuelos A; Reyes E; Ocadiz R; Alvarez E; Moreno M; Monroy A; Gariglio P
J Pharmacol Exp Ther; 2003 Aug; 306(2):671-80. PubMed ID: 12750435
[TBL] [Abstract][Full Text] [Related]
20. Codon 72 polymorphism of p53 and HPV type 16 E6 variants as risk factors for patients with squamous epithelial lesion of the uterine cervix.
Burroni E; Bisanzi S; Sani C; Puliti D; Carozzi F
J Med Virol; 2013 Jan; 85(1):83-90. PubMed ID: 23124863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]